Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2011

Gillies Stephen D, Lan Yan, Hettmann Thore, Brunkhorst Beatrice, Sun Yaping, Mueller Stefan O, Lo Kin-Ming

Abstract excerpt

PURPOSE: The goal of the study was to engineer a form of interleukin 2 (IL-2) that, when delivered as a tumor-specific antibody fusion protein, retains the ability to stimulate an antitumor immune response via interaction with the high-affinity IL-2 receptor but has lower toxicity because of the reduced activation of the intermediate-affinity IL-2 receptor. EXPERIMENTAL DESIGN: We investigated changes in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Immunoglobulin Variable Region

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interleukin-2

Share to Macaca fascicularis

Share to Multiple Myeloma

Share to Neuroblastoma

Share to Protein Engineering

Share to Receptors, Interleukin-2

Source

Identifiers

PMID: 21531812
DOI: 10.1158/1078-0432.CCR-10-2921

Genes

NHS
EMD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.PMID 21531812Read ↗

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read ↗

Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.Semantic proximity Read ↗

Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T cell responses during chronic viral infectionSemantic proximity Read ↗

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategiesSemantic proximity Read ↗

IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy.Semantic proximity Read ↗

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protectionSemantic proximity Read ↗

A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo.Semantic proximity Read ↗

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organismSemantic proximity Read ↗

Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology.Semantic proximity Read ↗

Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.Semantic proximity Read ↗

Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.Semantic proximity Read ↗

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.